Search

Your search keyword '"Furman, R"' showing total 103 results

Search Constraints

Start Over You searched for: Author "Furman, R" Remove constraint Author: "Furman, R" Publication Year Range Last 10 years Remove constraint Publication Year Range: Last 10 years
103 results on '"Furman, R"'

Search Results

1. Comprehensive Analysis of Pain Syndrome in Patients With Mandibular Fractures Treated With Nucleo CMP Forte

2. Zilovertamab vedotin (MK‐2140) in relapsed or refractory (R/R) non‐Hodgkin lymphoma (NHL): 14‐month follow‐up of the phase 1 waveLINE‐001 study

4. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

5. P1130: ACALABRUTINIB IN TREATMENT-NAIVE OR RELAPSED/REFRACTORY WALDENSTRÖM MACROGLOBULINEMIA: 5-YEAR FOLLOW-UP OF A PHASE 2, SINGLE-ARM STUDY

6. P1231: ZILOVERTAMAB VEDOTIN (MK-2140) FOR THE TREATMENT OF NON-HODGKIN LYMPHOMA: THE PHASE 1 DOSE ESCALATION AND COHORT EXPANSION WAVELINE-001 STUDY OF AN ANTI-ROR1 ANTIBODY-DRUG CONJUGATE

7. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen

9. Updated efficacy including subgroup analyses and safety in the phase 3 RESONATETM trial of ibrutinib versus ofatumumab in previously treated chronic lymphocytic leukaemia/small lymphocytic lymphoma: 35

10. Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors: 34

11. FIRST RESULTS OF A HEAD‐TO‐HEAD TRIAL OF ACALABRUTINIB VERSUS IBRUTINIB IN PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA

12. Evidence for children's online integration of simultaneous information from speech and iconic gestures: An ERP study

13. Health care social work

15. PHASE I CLINICAL TRIAL OF CD19-TARGETED 19-28Z/4-1BBL “ARMORED” CAR T CELLS IN PATIENTS WITH RELAPSED OR REFRACTORY NHL AND CLL INCLUDING RICHTER TRANSFORMATION

16. A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukaemia Applicable to Patients Treated with Novel Therapies and Standard of Care

20. Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE study in patients with previously treated CLL/SLL

21. Ibrutinib in previously treated chronic lymphocytic leukemia patients with autoimmune cytopenias in the RESONATE study

22. Mutations in NOTCH1 PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

23. PATTERNS OF IDELALISIB TREATMENT-EMERGENT LYMPHOCYTOSIS IN PATIENTS WITH CLL OR SLL

24. Creating Criminals: Australia's response to asylum seekers and refugees

26. Health-related quality of life impact of idelalisib in patients with relapsed chronic lymphocytic leukemia (CLL): phase 3 results

27. Second interim analysis of a phase 3 study of idelalisib plus rituximab (R) for relapsed chronic lymphocytic leukaemia (CLL): efficacy analysis in patient subpopulations with Del(17p) and other adverse prognostic factors

28. Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion

29. Results from the phase 2 RESONATE (TM)-17 trial: Efficacy and safety of Ibrutinib in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma with Del17p

30. 21 SF3B1 MUTATIONS INDUCE ABERRANT SPLICING LEADING TO A BLOCK IN ERYTHROID DIFFERENTIATION AND COMPETITIVE ADVANTAGE

31. Ofatumumab monotherapy in fludarabine-refractory chronic lymphocytic leukemia: final results from a pivotal study

32. EFFICACY OF NUCLEO C. M. P. FORTE IN RESTORATIVE THERAPY AFTER NERVE INJURY.

33. 456 SF3B1 mutations induce disease relevant aberrant mRNA splicing in cancer and confer sensitivity to spliceosome inhibition

34. Mutations in NOTCH1PEST domain orchestrate CCL19-driven homing of chronic lymphocytic leukemia cells by modulating the tumor suppressor gene DUSP22

35. Acalabrutinib monotherapy for treatment of chronic lymphocytic leukaemia (ACE-CL-001): analysis of the Richter transformation cohort of an open-label, single-arm, phase 1–2 study

36. Final Results of a Randomized, Phase III Study of Rituximab With or Without Idelalisib Followed by Open-Label Idelalisib in Patients With Relapsed Chronic Lymphocytic Leukemia

37. Monitoring and Managing BTK Inhibitor Treatment-Related Adverse Events in Clinical Practice

38. Impact of idelalisib on health-related quality of life in patients with relapsed chronic lymphocytic leukemia in a phase III randomized trial

39. Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies

40. Acalabrutinib monotherapy in patients with relapsed/refractory chronic lymphocytic leukemia: updated phase 2 results

41. Tumour debulking and reduction in predicted risk of tumour lysis syndrome with single-agent ibrutinib in patients with chronic lymphocytic leukaemia

42. Creating Criminals: Australia's response to asylum seekers and refugees

43. Hands of confidence: When gestures increase confidence in spatial problem-solving.

44. Biomarkers of Progression and Risk Stratification in Asymptomatic Waldenström Macroglobulinemia.

45. Mass spectrometry in gene therapy: Challenges and opportunities for AAV analysis.

46. Venetoclax retreatment of patients with chronic lymphocytic leukemia after a previous venetoclax-based regimen.

47. Free Radical Chain Reactions and Polyunsaturated Fatty Acids in Brain Lipids.

48. Serologic response to mRNA COVID-19 vaccination in lymphoma patients.

49. Sequential intensive chemotherapy followed by autologous or allogeneic transplantation for refractory lymphoma.

50. Using continuous chromatography methodology to achieve high-productivity and high-purity enrichment of charge variants for analytical characterization.

Catalog

Books, media, physical & digital resources